Clinical Trial Detail

NCT ID NCT02204098
Title Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Letrozole

Anastrozole

Goserelin

Exemestane

Tamoxifen

Age Groups: adult

Additional content available in CKB BOOST